Niki BioSolutions closes reverse merger with DiamiR, begins trading as NIKI

summarizeSummary

Aptorum Group and DiamiR Biosciences completed their reverse merger, forming Niki BioSolutions (NIKI). The deal includes a 1-for-10 reverse split, new governance with DiamiR control, and a 4.5M share equity plan.

check_boxKey Events · M&A and Partnerships · APM

• Merger Closed, New Entity Formed

  On July 20, 2026, Aptorum Group and DiamiR Biosciences completed their reverse merger, creating Niki BioSolutions, which now trades as NIKI on Nasdaq. Aptorum shareholders received 814,375 common shares and 179,693 Series A preferred shares, while DiamiR stockholders obtained 1,979,216 common shares, securing majority ownership.

• Reverse Stock Split Executed

  A 1-for-10 reverse split took effect, reducing outstanding Class A ordinary shares from approximately 6.35M to roughly 634,682 and Class B from about 1.80M to 179,693. The move aims to satisfy Nasdaq's minimum bid price requirement.

• New Governance and Board

  The board now consists of Ian Huen as Chairman, Kira Sheinerman as Director, and three independent directors. Under a Stockholders Agreement, Sheinerman—as Primary Stockholder—gains the right to designate up to two directors and veto power over major corporate actions, including equity issuances exceeding 10% and changes to the CEO or CFO.

• Equity Incentive Plan Adopted

  The 2026 Equity Incentive Plan reserves 4.5M shares for awards, with annual increases of up to 5% of outstanding shares beginning in 2027. This creates a pool for future employee and director compensation.

auto_awesomeAnalysis · APM · Industrial Applications And Services

Today marks the close of the long-awaited reverse merger between Aptorum Group and DiamiR Biosciences, giving birth to Niki BioSolutions. The transaction reshapes the company into a diagnostics-focused entity with a new board, governance framework, and equity plan. Existing Aptorum shareholders received 814,375 common shares and 179,693 non-voting preferred shares, while DiamiR stockholders obtained 1,979,216 common shares—handing majority control to DiamiR holders. To maintain Nasdaq listing compliance, a 1-for-10 reverse split was executed. The new stockholders agreement vests significant governance rights in DiamiR co-founder Kira Sheinerman, including board designation and veto power over major corporate actions. This is a thesis-altering event that redefines the company's identity, strategy, and ownership.